This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Higher Testing to Aid Quest Diagnostics' (DGX) Q3 Earnings
by Zacks Equity Research
Quest Diagnostics (DGX) is expected to report strong improvement in COVID-19 antibody and molecular diagnostic testing volume in Q3.
Quest Diagnostics (DGX) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Quest Diagnostics (DGX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Quest Diagnostics (DGX) Flat As Market Gains: What You Should Know
by Zacks Equity Research
Quest Diagnostics (DGX) closed at $116.67 in the latest trading session, marking no change from the prior day.
Quest Diagnostics (DGX) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Quest Diagnostics (DGX) closed at $116.21 in the latest trading session, marking a +0.71% move from the prior day.
Will Quest Diagnostics (DGX) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Quest Diagnostics (DGX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Quest Diagnostics' 3-in-1 Coronavirus Test Launch Well Timed
by Zacks Equity Research
According to Quest Diagnostics (DGX), under such situation, laboratory testing that can reliably identify the virus causing disease will be critical to mobilize effective patient care.
3 Beaten-Down MedTech Stocks to Grab Amid Market Meltdown
by Sriparna Ghosal
These cheap MedTech stocks are currently flourishing on the back of a number of positive developments.
Quest Diagnostics (DGX) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Quest Diagnostics (DGX) closed at $114.49 in the latest trading session, marking a +0.74% move from the prior day.
Quest Diagnostics Partners in Pilot Program for COVID-19 Test
by Zacks Equity Research
Quest Diagnostics (DGX) to provide online test results for COVID-19 samples collected via drone-delivered at-home self-collection kits as part of a pilot program.
Quest Diagnostics (DGX) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Quest Diagnostics (DGX) closed at $109.19 in the latest trading session, marking a -1.91% move from the prior day.
DGX, NKLA, NKE and TSLA as Zacks Bull and Bear of the Day
by Zacks Equity Research
DGX, NKLA, NKE and TSLA as Zacks Bull and Bear of the Day
Why You Shouldn't Bet Against Quest Diagnostics (DGX) Stock?
by Zacks Equity Research
Quest Diagnostics (DGX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Bull Of The Day: Quest Diagnostics (DGX)
by Daniel Laboe
Quest Diagnostics (DGX) has been one of the coronavirus heroes, having performed 14.4 million COVID-19 diagnostics tests and 3.6 million antibody tests
Quest Diagnostics New Tests Uptake Strong Amid Coronavirus Woe
by Zacks Equity Research
Heavy demand for COVID-19 molecular testing helps partially offset the base volume decline for Quest Diagnostics (DGX).
Has Quest Diagnostics (DGX) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (DGX) Outperforming Other Medical Stocks This Year?
The Zacks Analyst Blog Highlights: MDRX, VEEV, DGX, TMO and ZM
by Zacks Equity Research
The Zacks Analyst Blog Highlights: MDRX, VEEV, DGX, TMO and ZM
Is Another Great Depression Imminent or Is it Just a Myth?
by Urmimala Biswas
Asian countries have already shown clear signs of major economic recession.
Thermo Fisher Expands Lab Plastic Making for Coronavirus Support
by Zacks Equity Research
Thermo Fisher (TMO) consumables already support critical COVID-19 work and include sample collection vials and lab essentials.
Quest Diagnostics (DGX) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Quest Diagnostics (DGX) closed the most recent trading day at $113.59, moving +0.77% from the previous trading session.
The Zacks Analyst Blog Highlights: Quest Diagnostics, Abbott, Quidel, QIAGEN and Thermo Fisher Scientific
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Quest Diagnostics, Abbott, Quidel, QIAGEN and Thermo Fisher Scientific
3 Med Info Stocks to Improve Portfolio Health Amid Coronavirus Woes
by Urmimala Biswas
Postponement of elective surgeries leading to lower product bookings cloud Zacks-Medical Info Systems industry prospects. However, coronavirus-led demand for contactless services should aid the space. TXG, MDRX, NXGN should be the forerunners.
Coronavirus Test Makers With Scope to Maximize Investor Benefits
by Urmimala Biswas
The surge in new coronavirus infections broadens the scope for antigen and antibody tests.
Quest Diagnostics (DGX) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Quest Diagnostics (DGX) closed at $107.05 in the latest trading session, marking a -0.33% move from the prior day.
Quest Diagnostics (DGX) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Quest Diagnostics (DGX) closed the most recent trading day at $110.69, moving +0.95% from the previous trading session.
3 Top Outpatient and Home Healthcare Stocks to Watch Out For
by Trina Mukherjee
Despite the challenges thrown by the COVID-19 pandemic, rising dependence on telehealth and AI's dominant role should drive the Zacks Medical - Outpatient and Home Healthcare industry. DVA, USPH and PNTG are well positioned to gain from the prospects.